Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by developing and commercializing differentiated and accessible medicines that address unmet medical needs. HZN-825 is a selective, orally active, small molecule lysophosphatidic acid 1 (LPA1/Edg-2) receptor inhibitor that has shown favorable effects in animal models of skin fibrosis and is currently in development for the treatment of diffuse cutaneous systemic sclerosis (dcSSc) and interstitial lung disease (ILD) indications.<br/>Various PK studies and <i>in vitro</i> ADME experiments have identified one main metabolite of HZN-825. In order to profile this metabolite, it was necessary to develop an efficient chemical process to allow for this molecule to be synthesized on scale. Synthetic challenges and solutions found for the construction of the highly unusual 5-hydroxy-2,3-dihydro-1H-indene-2-carboxylic acid are presented in this poster.

Chemical route development and optimization of a 5-hydroxy-2,3-dihydro-1H-indene-2-carboxylic acid compound

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.